Table 1.
Toxicity profiling of a broad range of clinical and literature kinase inhibitors a,b,c.
| Name | CM | CMI | ROS | GSH | NMI1 | CC | NMI2 | MMP | CHI |
|---|---|---|---|---|---|---|---|---|---|
| Ponatinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.95 | 0.99 | 1.00 | 0.95 |
| Dacomitinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.98 | 0.99 | 1.00 | 0.94 |
| Bosutinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.91 | 1.00 | 1.00 | 0.94 |
| Vandetanib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.94 | 1.00 | 1.00 | 0.93 |
| Osimertinib | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 | 0.96 | 0.99 | 1.00 | 0.93 |
| Palbociclib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.98 | 0.99 | 1.00 | 0.93 |
| Sunitinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.93 | 0.99 | 1.00 | 0.93 |
| Crizotinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.96 | 0.99 | 1.00 | 0.92 |
| Canertinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.68 | 1.00 | 1.00 | 0.92 |
| Afatinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.93 | 0.99 | 1.00 | 0.92 |
| Tesevatinib | 1.00 | 1.00 | 1.00 | 1.00 | 0.91 | 0.96 | 0.99 | 1.00 | 0.92 |
| Cobimetinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.95 | 1.00 | 1.00 | 0.91 |
| Pelitinib | 1.00 | 1.00 | 1.00 | 1.00 | 0.77 | 0.95 | 0.99 | 1.00 | 0.91 |
| Ibrutinib | 1.00 | 1.00 | 1.00 | 1.00 | 0.97 | 0.99 | 0.98 | 1.00 | 0.90 |
| Lapatinib | 1.00 | 1.00 | 0.90 | 0.96 | 0.97 | 0.93 | 0.92 | 1.00 | 0.89 |
| Sorafenib | 1.00 | 1.00 | 1.00 | 0.99 | 1.00 | 0.87 | 0.99 | 1.00 | 0.88 |
| Neratinib | 1.00 | 1.00 | 1.00 | 0.98 | 0.97 | 0.83 | 1.00 | 1.00 | 0.87 |
| Regorafenib | 0.99 | 0.97 | 1.00 | 0.89 | 1.00 | 0.89 | 0.98 | 1.00 | 0.85 |
| Gefitinib | 1.00 | 0.99 | 0.93 | 0.97 | 0.61 | 0.93 | 0.94 | 0.99 | 0.80 |
| Poziotinib | 1.00 | 0.99 | 0.40 | 0.98 | 0.98 | 0.97 | 0.89 | 0.99 | 0.80 |
| Saracatinib | 1.00 | 0.92 | 0.72 | 0.93 | 0.81 | 0.76 | 0.78 | 0.71 | 0.69 |
| Alectinib | 1.00 | 0.98 | 0.99 | 0.97 | 0.84 | 0.054 | 0.036 | 0.15 | 0.55 |
| Vemurafenib | 0.77 | 0.52 | 0.95 | 0.22 | 0.99 | 0.31 | 0.89 | 0.37 | 0.51 |
| Cabozantinib | 0.94 | 0.73 | 0.080 | 0.029 | 0.49 | 0.17 | 0.77 | 0.70 | 0.48 |
| Pazopanib | 0.73 | 0.12 | 0.73 | 0.22 | 0.27 | 0.34 | 0.078 | 0.71 | 0.46 |
| Trametinib | 0.86 | 0.83 | 0.34 | 0.15 | 0.53 | 0.21 | 0.073 | 0.10 | 0.41 |
| Erlotinib | 0.77 | 0.50 | 0.13 | 0.63 | 0.10 | 0.10 | 0.062 | 0.12 | 0.40 |
| Ruxolitinib | 0.90 | 0.19 | 0.45 | 0.089 | 0.16 | 0.30 | 0.061 | 0.23 | 0.39 |
| Sapitinib | 0.63 | 0.30 | 0.024 | 0.28 | 0.32 | 0.43 | 0.28 | 0.22 | 0.38 |
| Dabrafenib | 0.37 | 0.50 | 0.22 | 0.089 | 0.21 | 0.49 | 0.058 | 0.45 | 0.37 |
| Tofacitinib | 0.36 | 0.042 | 0.034 | 0.032 | 0.056 | 0.11 | 0.14 | 0.12 | 0.23 |
a Abbreviations from columns left to right. CM: Cell morphology; CMI: Cell membrane integrity; ROS: Reactive oxygen species; GSH: Glutathione; NMI1: Nuclear membrane integrity 1; CC: Cell Cycle; NMI2: Nuclear membrane integrity 2; MMP: Mitochondrial membrane potential; CHI: Cell Health Index. b Traffic light colouring matching classifier values (Red–Green: high toxicity risk–low toxicity risk). c all n = 2.